[Antifungal therapy for infants, children and adolescents with suspected or documented invasive fungal infection].
Fungal nosocomial infections have gradually and consistently increased since the 90s.This increasing threat is closely related with the growing number of people with immune system disorders and their survival. It is also related with the destruction of their physical barriers against infection due to the use of cytotoxic drugs or invasive procedures, such is the case of cancer patients and bone marrow and solid organ transplant patients. Increased survival of patients with congenital or acquired immunodeficiency, premature babies and patients with complex congenital malformations, especially in the gastrointestinal tract, also add up to this scenario. The occurrence of yeast and filamentous fungi infections, especially of the Candida species, has been on the rise. Azole agents overuse, especially fluconazole, for the treatment and prophylaxis of fungal infections has put selective pressure on Candida spp. which resulted in an increase of non-albican species such as C. krusei, C. glabrata and C. famata, among others, as well as their growing resistance to these antifungal agents.
Odio
C M
CM
Escuela de Medicina, Universidad de Ciencias Medicas, Universidad de Costa Rica, San Jose, Costa Rica.
D000293:Adolescent; D000935:Antifungal Agents / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects; D002177:Candidiasis / Q000188:drug therapy / Q000453:epidemiology / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D005334:Fever / Q000150:complications; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009181:Mycoses / Q000188:drug therapy* / Q000453:epidemiology / Q000473:pathology; D009369:Neoplasms / Q000150:complications; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications; D014230:Triazoles / Q000627:therapeutic use
D000935:Antifungal Agents; D000970:Antineoplastic Agents; D014230:Triazoles